Company research
Arcturus Therapeutics Ltd.
CIK 1566049Updated Nov 16, 2026
Name history
ALCOBRA LTD. · through Nov 13, 2017
Filing activity
Latest filing
50 filings on record · CT ORDER, SC 13G/A, UPLOAD, CORRESP, 8-K, S-8.
Recent filings
Show 5 more recent filings
Financials
FY 2018 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 44,198,000Source | 52,024,000Source | 51,568,000Source | 71,683,000Source |
| Property, Plant and Equipment, NetUSD | 1,975,000Source | 1,049,000Source | 240,000Source | 227,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 36,709,000Source | 24,965,000Source | 2,304,000Source | 16,658,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 4,481,000Source | 480,000Source | — | — |
| Assets, CurrentUSD | 41,828,000Source | 50,868,000Source | 51,299,000Source | 52,346,000Source |
| Other Assets, NoncurrentUSD | — | 107,000Source | — | — |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 30,556,000Source | 18,230,000Source | — | — |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 214,000Source | 212,000Source | 74,000Source | 74,000Source |
| Additional Paid in CapitalUSD | 58,302,000Source | 56,674,000Source | 142,780,000Source | 140,274,000Source |
| Retained Earnings (Accumulated Deficit)USD | -44,874,000Source | -23,089,000Source | -95,620,000Source | -71,017,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | — | -3,000Source | -6,000Source | — |
| Stockholders' Equity Attributable to ParentUSD | 13,642,000Source | 33,794,000Source | 47,228,000Source | 69,331,000Source |
| Liabilities and EquityUSD | 44,198,000Source | 52,024,000Source | 51,568,000Source | 71,683,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 12,577,000Source | 11,040,000Source | 4,340,000Source | 2,352,000Source |
| Accounts Payable, CurrentUSD | 2,398,000Source | 1,790,000Source | — | — |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 3,907,000Source | 2,793,000Source | 2,520,000Source | 888,000Source |
| Deferred Revenue, CurrentUSD | 6,272,000Source | 6,457,000Source | — | — |
| Deferred Revenue, NoncurrentUSD | 7,534,000Source | 7,190,000Source | — | — |
| Long-term Debt, Excluding Current Maturities | — | — | — | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 9,911,000Source | — | — | — |
| Short-term InvestmentsUSD | — | 23,608,000Source | 33,000,000Source | 34,022,000Source |
cash flow · annual statements
| Line item | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 1,259,000Source | 2,170,000Source | 2,500,000Source | 2,365,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 4,001,000Source | -3,153,000Source | — | — |
| Increase (Decrease) in Accounts PayableUSD | 578,000Source | -1,537,000Source | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -20,760,000Source | — | -19,241,000Source | -18,148,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 22,134,000Source | — | 4,881,000Source | -33,842,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 1,478,000Source | 251,000Source | 74,000Source | 181,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 10,204,000Source | — | 6,000Source | 66,472,000Source |
| Payments of Ordinary Dividends, Common StockUSD | 0Source | 0Source | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 11,578,000Source | — | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 36,816,000Source | 25,238,000Source | — | — |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 146,000Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 1,259,000Source | 2,170,000Source | — | — |
| DepreciationUSD | — | — | 61,000Source | 51,000Source |
| General and Administrative ExpenseUSD | 20,582,000Source | 7,572,000Source | 5,357,000Source | 4,992,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | — | — |
| Income (Loss) from Equity Method InvestmentsUSD | -302,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | 1,000Source | 73,000Source | 51,000Source |
| Induced Conversion of Convertible Debt ExpenseUSD | — | 348,000Source | — | — |
| Investment Income, InterestUSD | — | — | 798,000Source | 338,000Source |
| Net Income (Loss) Attributable to ParentUSD | -21,785,000Source | -10,902,000Source | -24,603,000Source | -19,449,000Source |
| Operating ExpensesUSD | 37,564,000Source | 23,490,000Source | — | — |
| Other Nonoperating Income (Expense)USD | 328,000Source | -409,000Source | — | — |
| Proceeds from Issuance of Common StockUSD | — | 477,000Source | — | — |
| Proceeds from Issuance of Long-term DebtUSD | 9,872,000Source | — | — | — |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | — | — | 1,604,000Source | — |
| Proceeds from Stock Options ExercisedUSD | 332,000Source | 711,000Source | 6,000Source | 13,000Source |
income statement · annual statements
| Line item | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|
| Total RevenueUSD | 15,753,000Source | 12,998,000Source | — | — |
| Operating Income (Loss)USD | -21,811,000Source | -10,492,000Source | -25,167,000Source | -19,698,000Source |
| Other Nonoperating Income (Expense)USD | 328,000Source | -409,000Source | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -21,785,000Source | -10,901,000Source | -24,530,000Source | -19,398,000Source |
| Income Tax Expense (Benefit)USD | — | 1,000Source | 73,000Source | 51,000Source |
| Net Income (Loss) Attributable to ParentUSD | -21,785,000Source | -10,902,000Source | -24,603,000Source | -19,449,000Source |
| Additional Financial Items | ||||
| Depreciation, Depletion and Amortization, NonproductionUSD | 582,000Source | 410,000Source | — | — |
| General and Administrative ExpenseUSD | 20,582,000Source | 7,572,000Source | 5,357,000Source | 4,992,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -21,604,000Source | -10,820,000Source | — | — |
| Income (Loss) from Equity Method InvestmentsUSD | -302,000Source | — | — | — |
| Interest ExpenseUSD | — | 150,000Source | 161,000Source | 38,000Source |
| Interest Income (Expense), NetUSD | — | — | 637,000Source | 300,000Source |
| Investment Income, InterestUSD | — | — | 798,000Source | 338,000Source |
| Operating ExpensesUSD | 37,564,000Source | 23,490,000Source | — | — |
| Research and Development ExpenseUSD | 16,982,000Source | 15,918,000Source | 18,391,000Source | 13,461,000Source |